脉血康胶囊联合阿托伐他汀钙对颈动脉粥样硬化及血清超敏C反应蛋白的影响

摘要

目的 观察脉血康胶囊联合阿托伐他汀钙对颈动脉粥样硬化及血清超敏C反应蛋白(hs-CRP)的影响.方法将80例颈动脉粥样硬化患者分为治疗组(40例)和对照组(40例).两组患者在给予常规基础药物治疗的同时,治疗组给予脉血康胶囊合用阿托伐他汀钙片,对照组给予阿托伐他汀钙片.两组疗程均为24周.观察两组患者治疗前及疗程结束后血清hs-CRP、血脂及颈动脉内膜-中层厚度(IMT)、斑块总积分的变化.结果两组患者治疗后血清hs-CRP、血脂及颈动脉IMT、斑块总积分均较治疗前显著降低(P ＜ 0.01或P ＜ 0.05),且治疗组上述指标下降幅度优于对照组(P ＜ 0.01或P ＜ 0.05).结论脉血康胶囊与阿托伐他汀钙联合应用对颈动脉粥样硬化发挥协同作用.在抗炎、调脂、抗动脉粥样硬化方面较单用阿托伐他汀钙更为有效.%Objective To observe effect of combined therapy of Maixuekang Capsule and Atorvastatin Calcium on carotid atherosclerosis and serum high sensitivity C-reaction protein (hs-CRP) in patients with carotid atherosclerosis. Methods 80 cases of patients with carotid atherosclerosis were divided into a treatment group (n = 40) and a control group (n = 40). All the patients were treated with usual therapy, the combined therapy with Maixuekang Capsule and Atorvastatin Calcium Tablets were added in the treatment group, the Atorvastatin Calcium Tablets were added in the control group. The changes of cases in two groups on serum hs-CRP, blood lipid levels, carotid intima-media thickness (IMT) and carotid atherosclerosis score were observed after treatment in 24 weeks. Results After treatment, serum hs-CRP, blood lipid levels, carotid IMT and carotid atherosclerosis score significantly decreased in both groups (P < 0.01 or P < 0.05), but the decrement was more obvious in the treatment group comparing with that in the control group (P < 0.01 or P < 0.05). Conclusion Maixuekang Capsule and Atorvastatin Calcium combined therapy has an-tiatherosclerotic effect. Effect of combined therapy of Maixuekang Capsule and Atorvastatin Calcium is more significant than that of Atorvastatin Calcium in inhibiting inflammatory immune reaction, reducing blood lipid levels and inhibiting atherosclerosis.